Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $400000.0.

  • Vivos Therapeutics' Depreciation and Depletion rose 30000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 12000.0%. This contributed to the annual value of $600000.0 for FY2024, which is 0.0% changed from last year.
  • Per Vivos Therapeutics' latest filing, its Depreciation and Depletion stood at $400000.0 for Q3 2025, which was up 30000.0% from $300000.0 recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Depreciation and Depletion ranged from a high of $400000.0 in Q3 2025 and a low of $80597.0 during Q2 2021
  • Its 5-year average for Depreciation and Depletion is $172663.0, with a median of $200000.0 in 2022.
  • Per our database at Business Quant, Vivos Therapeutics' Depreciation and Depletion soared by 80067.26% in 2021 and then plummeted by 5000.0% in 2023.
  • Over the past 5 years, Vivos Therapeutics' Depreciation and Depletion (Quarter) stood at $100000.0 in 2021, then surged by 200.0% to $300000.0 in 2022, then crashed by 33.33% to $200000.0 in 2023, then changed by 0.0% to $200000.0 in 2024, then surged by 100.0% to $400000.0 in 2025.
  • Its Depreciation and Depletion stands at $400000.0 for Q3 2025, versus $300000.0 for Q2 2025 and $200000.0 for Q1 2025.